C. difficile 위험도


Mild CAP, pharyngitis, tonsillitis, SSTIAECBAcute bacterial sinusitisChancroid, non-gonococcal urethritis or cervicitisGonococcal urethritis or cervicitis500 mg IV/PO 1 dose, then 250 mg PO q24h x4d500 mg IV/PO 1 dose, then 250 mg PO q24h x4d 500 mg IV/PO q24h x3d500 mg IV/PO q24h x3d1 g PO 1 dose2 g PO 1 doseNo renal dose adjustment

Safety and efficacy of IV form in pediatric patients <16y of age have not been established

Acute otitis media 30 mg/kg PO 1 dose 10 mg/kg PO q24h x3d 10 mg/kg PO 1 dose, then 5 mg/kg PO q24h x4d

Acute bacterial sinusitis 10 mg/kg PO q24h x3d

CAP 10 mg/kg PO 1 dose, then 5 mg/kg PO q24h x4d

Pharyngitis, tonsillitis 12 mg/kg PO q24h x5dNo renal dose adjustment

No dose adjustment

General Information

  • Community-acquired pneumonia

  • Pertussis

  • Upper respiratory tract infections

  • Chlamydial infections

  • Mycobacterial infections

  • Mycobacterium avium complex (MAC) prophylaxis in HIV patients

Monitor QTc in patients with increased risk.


  • Abdominal pain

  • Diarrhea

  • Flatulence

  • Nausea

  • Vomiting

  • Headache

  • Abnormal vision

  • Increased liver enzymes

  • Injection site reaction


  • Prolonged QT interval

  • Torsades de pointes

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Generalized exanthematous pustulosis, acute

  • Congenital hypertrophic pyloric stenosis

  • Hepatitis

  • Liver failure

  • Hepatic necrosis

  • Maysthenia gravis

  • Exacerbation of myasthenic crisis

  • Eaton-Lambert syndrome

  • Corneal erosion

  • Increases cyclosporine levels

  • May increase digoxin levels

  • Statins increased risk of rhabdomyolysis


  • QT interval prolonging drugs

Multiple drug-drug interactions

Antimicrobial class: Macrolide

Pregnancy category: B

Average serum half life: 68 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor

Very high tissue penetration and concentration intracellularly means in vivo activity may not be predicted by in vitro testing (e.g. Salmonella species).

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.